News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,215 Results
Type
Article (13844)
Company Profile (101)
Press Release (252270)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88128)
Career Advice (465)
Deals (15352)
Drug Delivery (67)
Drug Development (36620)
Employer Resources (49)
FDA (6303)
Job Trends (6207)
News (150351)
Policy (14062)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (442)
Accelerated approval (2)
Adcomms (6)
Allergies (36)
Alliances (23244)
ALS (37)
Alzheimer's disease (396)
Antibody-drug conjugate (ADC) (42)
Approvals (6343)
Artificial intelligence (112)
Autoimmune disease (9)
Automation (4)
Bankruptcy (152)
Best Places to Work (4372)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (643)
Cardiovascular disease (72)
Career advice (409)
Career pathing (12)
CAR-T (22)
Cell therapy (89)
Cervical cancer (4)
Clinical research (30952)
Collaboration (352)
Compensation (155)
Complete response letters (17)
COVID-19 (760)
CRISPR (22)
C-suite (127)
Cystic fibrosis (37)
Data (664)
Denatured (15)
Depression (10)
Diabetes (83)
Diagnostics (1325)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (66)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32232)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37622)
Executive appointments (400)
FDA (6739)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (215)
Gene editing (40)
Generative AI (9)
Gene therapy (101)
GLP-1 (350)
Government (1301)
Grass and pollen (3)
Guidances (19)
Healthcare (3567)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (35)
Indications (14)
Infectious disease (795)
Inflammatory bowel disease (56)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5880)
IRA (29)
Job creations (2054)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (181)
Leadership (4)
Legal (3442)
Liver cancer (19)
Lung cancer (87)
Lymphoma (57)
Machine learning (2)
Management (16)
Manufacturing (162)
MASH (33)
Medical device (1280)
Medtech (1282)
Mergers & acquisitions (9679)
Metabolic disorders (265)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (586)
NextGen: Class of 2025 (1586)
Non-profit (599)
Northern California (729)
Now hiring (8)
Obesity (151)
Opinion (119)
Ovarian cancer (22)
Pain (53)
Pancreatic cancer (15)
Parkinson's disease (47)
Partnered (7)
Patents (121)
Patient recruitment (29)
Peanut (10)
People (29022)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8056)
Phase II (13096)
Phase III (11749)
Pipeline (465)
Policy (72)
Postmarket research (1401)
Preclinical (3232)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (170)
Real estate (2637)
Recruiting (17)
Regulatory (10147)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (37)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Southern California (746)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1630)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (31)
The Weekly (30)
United States (7429)
Vaccines (156)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Today (58)
Last 7 days (265)
Last 30 days (903)
Last 365 days (11758)
2025 (3882)
2024 (12506)
2023 (14252)
2022 (19576)
2021 (20084)
2020 (19054)
2019 (14902)
2018 (11721)
2017 (13901)
2016 (13136)
2015 (15487)
2014 (12425)
2013 (10608)
2012 (11396)
2011 (11923)
2010 (10894)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (56)
Arkansas (3)
Asia (20153)
Australia (2618)
California (1778)
Canada (929)
China (247)
Colorado (71)
Connecticut (70)
Delaware (60)
Europe (39542)
Florida (338)
Georgia (39)
Idaho (9)
Illinois (201)
India (16)
Indiana (136)
Iowa (1)
Japan (96)
Kansas (58)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (263)
Massachusetts (1532)
Michigan (30)
Minnesota (95)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (784)
New Mexico (7)
New York (531)
North Carolina (402)
North Dakota (2)
Northern California (729)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (458)
Puerto Rico (8)
Rhode Island (10)
South America (502)
South Carolina (2)
Southern California (746)
Tennessee (34)
Texas (236)
Utah (34)
Virginia (77)
Washington D.C. (31)
Washington State (123)
Wisconsin (17)
266,215 Results for "mallinckrodt pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
Both Mallinckrodt and Endo have previously declared bankruptcy, linked to opioid-related lawsuits.
March 13, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader
March 13, 2025
·
28 min read
Mergers & Acquisitions
Mallinckrodt Offloads Therakos Photopheresis Business to CVC Capital Partners for $925M
The specialty pharmaceutical company has twice filed for bankruptcy in recent years, driven by opioid-related litigation. Mallinckrodt’s deal with CVC will allow it to pay off more than half of its net debt.
August 6, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results
February 28, 2025
·
2 min read
Press Releases
Mallinckrodt plc Reschedules Release of Fourth Quarter and Fiscal Year 2024 Financial Results to Thursday, March 13, 2025
March 11, 2025
·
2 min read
Press Releases
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides 2025 Guidance
March 14, 2025
·
53 min read
Press Releases
Mallinckrodt Completes Divestiture of Therakos® Business
December 3, 2024
·
9 min read
Business
Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance
Mallinckrodt plc, a global specialty pharmaceutical company, reported its financial results for the first quarter ended March 29, 2024.
May 9, 2024
·
26 min read
Press Releases
CVC Completes Acquisition of Therakos from Mallinckrodt
December 2, 2024
·
3 min read
Business
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
Mallinckrodt plc (“Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today reported its financial results for the fourth quarter and fiscal year ended December 29, 2023.
March 26, 2024
·
52 min read
1 of 26,622
Next
